Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol. / Baandrup, Lone; Fagerlund, Birgitte; Jennum, Poul; Lublin, Henrik; Hansen, Jane L; Winkel, Per; Gluud, Christian Nyfeldt; Oranje, Bob; Glenthoj, Birte Y.

In: B M C Psychiatry, Vol. 11, 2011, p. 160.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Baandrup, L, Fagerlund, B, Jennum, P, Lublin, H, Hansen, JL, Winkel, P, Gluud, CN, Oranje, B & Glenthoj, BY 2011, 'Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol', B M C Psychiatry, vol. 11, pp. 160. https://doi.org/10.1186/1471-244X-11-160

APA

Baandrup, L., Fagerlund, B., Jennum, P., Lublin, H., Hansen, J. L., Winkel, P., Gluud, C. N., Oranje, B., & Glenthoj, B. Y. (2011). Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol. B M C Psychiatry, 11, 160. https://doi.org/10.1186/1471-244X-11-160

Vancouver

Baandrup L, Fagerlund B, Jennum P, Lublin H, Hansen JL, Winkel P et al. Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol. B M C Psychiatry. 2011;11:160. https://doi.org/10.1186/1471-244X-11-160

Author

Baandrup, Lone ; Fagerlund, Birgitte ; Jennum, Poul ; Lublin, Henrik ; Hansen, Jane L ; Winkel, Per ; Gluud, Christian Nyfeldt ; Oranje, Bob ; Glenthoj, Birte Y. / Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol. In: B M C Psychiatry. 2011 ; Vol. 11. pp. 160.

Bibtex

@article{f64cea7fa7234a97a3c19480703a7d6c,
title = "Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol",
abstract = "Treatment of schizophrenia frequently includes prolonged benzodiazepine administration despite a lack of evidence of its use. It is often difficult to discontinue benzodiazepines because of the development of dependence. We aim to assess if melatonin can facilitate the withdrawal of prolonged benzodiazepine administration in patients with schizophrenia. Furthermore, we aim to investigate the association of benzodiazepine dose reduction with the following clinically important variables: sleep, psychophysiology, cognition, social function, and quality of life.",
author = "Lone Baandrup and Birgitte Fagerlund and Poul Jennum and Henrik Lublin and Hansen, {Jane L} and Per Winkel and Gluud, {Christian Nyfeldt} and Bob Oranje and Glenthoj, {Birte Y}",
year = "2011",
doi = "http://dx.doi.org/10.1186/1471-244X-11-160",
language = "English",
volume = "11",
pages = "160",
journal = "B M C Psychiatry",
issn = "1471-244X",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol

AU - Baandrup, Lone

AU - Fagerlund, Birgitte

AU - Jennum, Poul

AU - Lublin, Henrik

AU - Hansen, Jane L

AU - Winkel, Per

AU - Gluud, Christian Nyfeldt

AU - Oranje, Bob

AU - Glenthoj, Birte Y

PY - 2011

Y1 - 2011

N2 - Treatment of schizophrenia frequently includes prolonged benzodiazepine administration despite a lack of evidence of its use. It is often difficult to discontinue benzodiazepines because of the development of dependence. We aim to assess if melatonin can facilitate the withdrawal of prolonged benzodiazepine administration in patients with schizophrenia. Furthermore, we aim to investigate the association of benzodiazepine dose reduction with the following clinically important variables: sleep, psychophysiology, cognition, social function, and quality of life.

AB - Treatment of schizophrenia frequently includes prolonged benzodiazepine administration despite a lack of evidence of its use. It is often difficult to discontinue benzodiazepines because of the development of dependence. We aim to assess if melatonin can facilitate the withdrawal of prolonged benzodiazepine administration in patients with schizophrenia. Furthermore, we aim to investigate the association of benzodiazepine dose reduction with the following clinically important variables: sleep, psychophysiology, cognition, social function, and quality of life.

U2 - http://dx.doi.org/10.1186/1471-244X-11-160

DO - http://dx.doi.org/10.1186/1471-244X-11-160

M3 - Journal article

VL - 11

SP - 160

JO - B M C Psychiatry

JF - B M C Psychiatry

SN - 1471-244X

ER -

ID: 40156269